drugset / Trial / NCT01818245
A Study of LY2605541 in Healthy Participants and in the Elderly
RandomizedCrossoverOpen-labelBasic science
Summary
This study will include 2 groups (cohorts) of participants: In Cohort A, this study will look at the amount of LY2605541 that is present in the body after it is injected in 3 different locations in the body of the same participant. At least 16 days will pass between each injection. In Cohort B, the study will look at how the body absorbs, distributes, and disposes of LY2605541 in participants aged 65 and over. Participants may enroll in only one cohort.
Timeline
- Start
- 2013-03
- Primary completion
- 2013-07
- Completion
- 2013-07
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Insulin Peglispro | Protein / enzyme biologic | 0.5 iu/kg | Subcutaneous |
Indications
No indication recorded.